A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Primary Glial Neoplasms of the Brain.

Conditions:		Primary Glial Neoplasms of Brain - Glioblastoma
Purpose:		A one time oral dose of ALA is taken before surgery. The medication makes the tumor visible under ultraviolet light which allow the surgeon to see more of the tumor for a more complete removal.
Study Summary:
Criteria:		Inclusion Criteria: - Suspected primary brain tumor - 18 years of age or more - Normal marrow and organ function - - Life expectancy not a consideration Exclusion Criteria: - Receiving any other investigational agents - History of allergic reactions to ALA - Personal or family history of prophorias - Liver disease in the past year - Uncontrolled intercurrent illness - Pregnant or Lactating women - Inability to undergo MRI with contrast
NCT ID:		NCT00961090
Primary Contact:		Principal Investigator Matthew R Quigley, MD West Penn Allegheny Health System Dorothy Packer, RN,BSN Phone: 412-359-6505 Email: dpacker@wpahs.org
Backup Contact:		Email: dcantell@wpahs.org Diane Cantella, RN,BSN Phone: 412+359-3353
Location Contact:		Pittsburgh, Pennsylvania 15212 United States Dorothy M Packer, RN, BSN Phone: 412-359-6505 Site Status: Recruiting

Data Source:		ClinicalTrials.gov
Date Processed:		May 23, 2013
Modifications to this listing:		Only selected fields are shown, please use the link below to view all information about this clinical trial.
Click to view Full Listing


If you would like to be contacted by the clinical trial representative please enter your contact information, then click "I Am Interested In This Study"

First Name:

Last Name:

Email Address:

Confirm Email:

Daytime Phone (eg. 555-555-5555):

City:

State:

Zip Code:

Best Time to Call:

Morning	Afternoon	Evening
Please contact me by email instead of calling.

Questions/Comments:

I have read and agree with the Privacy Policy

I have reviewed the eligibility criteria and believe I am eligible for this clinical trial

I would like to be notified about new clinical trials.